Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Public ClinicalTrials.gov record NCT00057811. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy
Study identification
- NCT ID
- NCT00057811
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Children's Oncology Group
- Network
- Enrollment
- 97 participants
Conditions and interventions
Conditions
- Childhood Burkitt Lymphoma
- Childhood Diffuse Large Cell Lymphoma
- Childhood Immunoblastic Large Cell Lymphoma
- Stage I Childhood Large Cell Lymphoma
- Stage I Childhood Small Noncleaved Cell Lymphoma
- Stage II Childhood Large Cell Lymphoma
- Stage II Childhood Small Noncleaved Cell Lymphoma
- Stage III Childhood Large Cell Lymphoma
- Stage III Childhood Small Noncleaved Cell Lymphoma
- Stage IV Childhood Large Cell Lymphoma
- Stage IV Childhood Small Noncleaved Cell Lymphoma
- Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
- cyclophosphamide Drug
- cytarabine Drug
- doxorubicin hydrochloride Drug
- etoposide Drug
- filgrastim Biological
- hydrocortisone sodium succinate Drug
- laboratory biomarker analysis Other
- leucovorin calcium Drug
- methotrexate Drug
- methylprednisolone Drug
- prednisone Drug
- rasburicase Drug
- rituximab Biological
- vincristine sulfate Drug
Drug · Biological · Other
Eligibility (public fields only)
- Age range
- 1 Year to 29 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2004
- Primary completion
- Sep 30, 2009
- Completion
- Jun 30, 2014
- Last update posted
- Sep 18, 2014
2004 – 2014
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Oncology Group | Arcadia | California | 91006-3776 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00057811, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2014 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00057811 live on ClinicalTrials.gov.